This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (14)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

Application for Human Renal Homotransplantation

TAKAO SONODA, MD; MINATO TAKAHA, MD; TAKAMITSU KUSUNOKI, MD

AMA Arch Surg. 1966;93(5):831-833.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

USING thoracic duct lymph drainage, Cronemiller and his associates¹ were able to reduce the blood urea nitrogen (BUN) level and remove edema in patients with uremia due to advanced chronic renal insufficiency. On the other hand, Dumont and Mulholland² indicated that thoracic duct drainage was effective in reducing ascites in patients with liver cirrhosis. In the field of organ transplantation, removal of lymphocytes from the body has drawn particular attention because lymphocytes are significantly involved in antibody production. Lymphocytes can be eliminated from the body of animals in any one of the following three ways: (1) the use of antilymphocytic immune serum^3-6; (2) selective irradiation by a β-emitting isotope^7-10; and (3) thoracic duct lymph drainage.^11,13 McGregor and Gowans¹¹ demonstrated that chronic thoracic duct lymph drainage can reduce the rat's lymphocytes in the peripheral blood, inhibit antibody production, and prolong skin homograft survival time. Samuelson . . . [Full Text PDF of this Article]

Author Affiliations
OSAKA, JAPAN

From the Department of Urology, Osaka University Medical School, Osaka.

Footnotes
Submitted for publication Feb 18, 1966.

Reprint requests to Department of Urology, Osaka University Hospital, Osaka University Medical School, Fukushima-Ku, Osaka, Japan (Dr. Sonoda).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?